Literature DB >> 28669726

Knockdown of frizzled-7 inhibits cell growth and metastasis and promotes chemosensitivity of esophageal squamous cell carcinoma cells by inhibiting Wnt signaling.

Xiaoping Liu1, Yanli Yan2, Weiping Ma2, Suge Wu2.   

Abstract

A growing body of evidence suggests that frizzled-7 (FZD7) is an important oncogene in multiple human malignancies and is involved in regulating sensitivity to chemotherapeutic drugs. However, little is known about the expression and function of FZD7 in esophageal squamous cell carcinoma (ESCC). In this study, we aimed to investigate the functional significance of FZD7 in ESCC. Here, we found that both mRNA and protein expression levels of FZD7 were highly upregulated in ESCC cell lines. The knockdown of FZD7 inhibited cell growth, induced cell apoptosis, and suppressed cell migration and invasion of ESCC cells in vitro. Furthermore, knockdown of FZD7 promoted chemosensitivity to cisplatin in ESCC cells and suppressed the expression of multidrug resistance protein 1. Moreover, the silencing of FZD7 also significantly impeded the activation of Wnt signaling in ESCC cells. Taken together, our study reveals an oncogenic role of FZD7 in the progression of ESCC and suggests that FZD7 might serve as a potential therapeutic target for treatment of ESCC.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug resistance; Esophageal squamous cell carcinoma; FZD7; Wnt

Mesh:

Substances:

Year:  2017        PMID: 28669726     DOI: 10.1016/j.bbrc.2017.06.185

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Signaling pathways and their potential therapeutic utility in esophageal squamous cell carcinoma.

Authors:  L K Kadian; M Arora; C P Prasad; R Pramanik; S S Chauhan
Journal:  Clin Transl Oncol       Date:  2022-01-06       Impact factor: 3.405

Review 2.  Frizzled Receptors as Potential Therapeutic Targets in Human Cancers.

Authors:  Chui-Mian Zeng; Zhe Chen; Li Fu
Journal:  Int J Mol Sci       Date:  2018-05-22       Impact factor: 5.923

3.  Determination of the relationship between doxorubicin resistance and Wnt signaling pathway in HeLa and K562 cell lines.

Authors:  Pelin Mutlu; Serap Yalçin Azarkan; Negar Taghavi Pourianazar; Meral Yücel; Ufuk Gündüz
Journal:  EXCLI J       Date:  2018-05-02       Impact factor: 4.068

4.  MicroRNA-488 inhibits endometrial glandular epithelial cell proliferation, migration, and invasion in endometriosis mice via Wnt by inhibiting FZD7.

Authors:  Hui Zhu; Xi-Xia Cao; Juan Liu; Hua Hua
Journal:  J Cell Mol Med       Date:  2019-02-07       Impact factor: 5.310

Review 5.  Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in cancer.

Authors:  Wing-Kee Lee; Thévenod Frank
Journal:  Cancer Drug Resist       Date:  2021-06-19

Review 6.  ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer.

Authors:  David Vrana; Viktor Hlavac; Veronika Brynychova; Radka Vaclavikova; Cestmir Neoral; Jiri Vrba; Rene Aujesky; Marcel Matzenauer; Bohuslav Melichar; Pavel Soucek
Journal:  Int J Mol Sci       Date:  2018-03-15       Impact factor: 5.923

Review 7.  Functional roles of circular RNAs during epithelial-to-mesenchymal transition.

Authors:  Bing-Qing Shang; Min-Le Li; Hao-Yu Quan; Ping-Fu Hou; Zhong-Wei Li; Su-Fang Chu; Jun-Nian Zheng; Jin Bai
Journal:  Mol Cancer       Date:  2019-09-16       Impact factor: 27.401

8.  Expression of LGR5, FZD7, TROY, and MIST1 in Perioperatively Treated Gastric Carcinomas and Correlation with Therapy Response.

Authors:  Antonia Freiin Grote; Christine Halske; Hans-Michael Behrens; Sandra Krüger; Franziska Wilhelm; Jan-Hendrik Egberts; Christoph Röcken
Journal:  Dis Markers       Date:  2019-11-19       Impact factor: 3.434

9.  Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides.

Authors:  Rudolph L Juliano
Journal:  NAR Cancer       Date:  2020-09-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.